Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts

Nuclear Medicine and Biology

Volumn 36, Issue 4, 2009, Pages 379-388

  Tsuji, Atsushi B ^a   Sogawa, Chizuru ^a   Sugyo, Aya ^a   Sudo, Hitomi ^a,b   Toyohara, Jun ^c   Koizumi, Mitsuru ^a   Abe, Masaaki ^b   Hino, Okio ^b   Harada, Yoshi nobu ^a   Furukawa, Takako ^a   Suzuki, Kazutoshi ^a   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

FDG; FLT; Mesothelioma; Positron emission tomography; Thiothymidine; Tumor mouse model

Indexed keywords

4 METHYL THIOTHYMIDINE C 11; FLUORO 3' DOXYTHYMIDINE F 18; FLUORO 3' DOXYTHYMIDINE H 3; FLUORODEOXYGLUCOSE C 14; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; THYMIDINE KINASE 1; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; TUMOR DIAGNOSIS; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; INJECTIONS, SUBCUTANEOUS; KI-67 ANTIGEN; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MICE; MICE, NUDE; PLEURAL CAVITY; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; TRANSPLANTATION, HETEROLOGOUS;

EID: 67349210019     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.01.018     Document Type: Article

References (21)

1. Robinson B.W., and Lake R.A. Advances in malignant mesothelioma. N Engl J Med 353 (2005) 1591-1603
2. Tsiouris A., and Walesby R.K. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 4 (2007) 344-352
3. Kanazawa N., Ioka A., Tsukuma H., Ajiki W., and Oshima A. Incidence and survival of mesothelioma in Osaka, Japan. Jpn J Clin Oncol 36 (2006) 254-257
4. Peto J., Decarli A., La Vecchia C., Levi F., and Negri E. The European mesothelioma epidemic. Br J Cancer 79 (1999) 666-672
5. Juweid M.E., and Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354 (2006) 496-507
6. Benard F., Sterman D., Smith R.J., Kaiser L.R., Albelda S.M., and Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114 (1998) 713-722
7. Shreve P.D., Anzai Y., and Wahl R.L. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19 (1999) 61-77
8. Love C., Tomas M.B., Tronco G.G., and Palestro C.J. FDG PET of infection and inflammation. Radiographics 25 (2005) 1357-1368
9. van Waarde A., Cobben D.C., Suurmeijer A.J., Maas B., Vaalburg W., de Vries E.F., et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 45 (2004) 695-700
10. Shields A.F., Grierson J.R., Dohmen B.M., Machulla H.J., Stayanoff J.C., Lawhorn-Crews J.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
11. Buck A.K., Halter G., Schirrmeister H., Kotzerke J., Wurziger I., Glatting G., et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44 (2003) 1426-1431
12. Toyohara J., Okada M., Toramatsu C., Suzuki K., and Irie T. Feasibility studies of 4′-[methyl-(11)C]thiothymidine as a tumor proliferation imaging agent in mice. Nucl Med Biol 35 (2008) 67-74
13. Toyohara J., Kumata K., Fukushi K., Irie T., and Suzuki K. Evaluation of 4′-[methyl-14C]thiothymidine for in vivo DNA synthesis imaging. J Nucl Med 47 (2006) 1717-1722
14. Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S., et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 97 (2006) 387-394
15. Martarelli D., Catalano A., Procopio A., Orecchia S., Libener R., and Santoni G. Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer 6 (2006) 130
16. Martin S.J., Eisenbarth J.A., Wagner-Utermann U., Mier W., Henze M., Pritzkow H., et al. A new precursor for the radiosynthesis of [18F]FLT. Nucl Med Biol 29 (2002) 263-273
17. Toyohara J., Hayashi A., Sato M., Tanaka H., Haraguchi K., Yoshimura Y., et al. Rationale of 5-(125)I-iodo-4′-thio-2′-deoxyuridine as a potential iodinated proliferation marker. J Nucl Med 43 (2002) 1218-1226
18. Hino O., Shiomi K., and Maeda M. Diagnostic biomarker of asbestos-related mesothelioma: example of translational research. Cancer Sci 98 (2007) 1147-1151
19. Fueger B.J., Czernin J., Hildebrandt I., Tran C., Halpern B.S., Stout D., et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 47 (2006) 999-1006
20. Dittmann H., Dohmen B.M., Paulsen F., Eichhorn K., Eschmann S.M., Horger M., et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 30 (2003) 1407-1412
21. Paproski R.J., Ng A.M., Yao S.Y., Graham K., Young J.D., and Cass C.E. The role of human nucleoside transporters in uptake of 3′-deoxy-3′-fluorothymidine. Mol Pharmacol 74 (2008) 1372-1380